

R-126

At  
cont.

Claim <sup>16</sup>~~14~~. A process for detecting the presence of cancerous or malignant tumor cells in a cell collection, comprising applying to said cell collection an anti-MALIGNIN product, whereby said anti-MALIGNIN product preferentially attaches to cancerous cells and can thereby be detected by attached visible or signal-emitting means.

Claim <sup>17</sup>~~15~~. A process for detecting the presence of cancerous or malignant tumor cells in a cell collection, comprising applying to said cell collection an anti-MALIGNIN product, and thereafter applying fluorescein-conjugated anti-anti-MALIGNIN thereto, whereby fluorescence occurs only in the cancerous tumor cells upon illumination.

Claim <sup>18</sup>~~16~~. The process according to claim <sup>15</sup>~~13~~ wherein said cancerous tumor cells are glial tumor cells.

Claim <sup>19</sup>~~17~~. The process according to claim <sup>15</sup>~~13~~ wherein said tumor cells are non-glial tumor cells.

Claim <sup>20</sup>~~18~~. The process according to claim <sup>16</sup>~~14~~ wherein said anti-MALIGNIN product is produced by the reaction of (a) a fluid or other mixture containing anti-MALIGNIN and (b) MALIGNIN.

Claim <sup>21</sup>~~19~~. The process according to claim <sup>20</sup>~~18~~ wherein said MALIGNIN is in the form of a complex with an inert carrier.

Claim <sup>22</sup>~~20~~. The process according to claim <sup>21</sup>~~19~~ wherein said inert carrier is bromoacetylcellulose.

Claim <sup>23</sup>~~21~~. The process according to claim <sup>17</sup>~~15~~ wherein said anti-MALIGNIN product is one which has been at least partially freed of substances which are less or non-reactive in fluorescent detection when applied to known cancerous cells.

R-126

Claim <sup>24</sup>~~22~~. The product produced in accordance with the process of claim <sup>23</sup>~~21~~.

Claim <sup>25</sup>~~23~~. The process according to claim <sup>16</sup>~~14~~ wherein said anti-MALIGNIN product is attached to a signal emitter, whereby those cancer cells to which said anti-MALIGNIN product has been preferentially attached can be detected.

Claim <sup>26</sup>~~24~~. The product comprising anti-MALIGNIN product attached to a signal emitter.

Claim <sup>27</sup>~~25~~. The process according to claim <sup>25</sup>~~23~~ wherein said anti-MALIGNIN product is directly attached to said signal emitter.

Claim <sup>28</sup>~~26~~. The process according to claim <sup>25</sup>~~23~~ wherein said anti-MALIGNIN product is indirectly attached to said signal emitter.

Claim <sup>29</sup>~~27~~. The process according to claim <sup>15</sup>~~13~~ wherein said cell collection is in vivo.

Claim <sup>30</sup>~~28~~. The process according to claim <sup>15</sup>~~13~~ wherein said cell collection is in vitro.

At  
cont.

31  
Claim 29. The process according to claim 14 wherein  
said anti-MALIGNIN product is the product produced in response  
to MALIGNIN, wherein said MALIGNIN is a product, derived from  
brain tumor cells, which forms a single line precipitate with  
its specific antibody in quantitative precipitin tests and  
in Ouchterlony gel diffusion tests, being soluble in water  
and aqueous solutions having an acid or neutral pH, and  
insoluble at an alkaline pH, and has a spectrophotometric  
absorption peak wave length of 280 mu, a molecular weight of  
about 10,000 and an amino acid composition approximately  
as follows:

A  
cont

B

	<u>Approximate No. of Residues</u>
Aspartic Acid	9
Threonine	5
Serine	5
Glutamic Acid	13
Proline	4
Glycine	6
Alanine	7
Valine	6
1/2 Cystine	1
Methionine	2
Isoleucine	4
Leucine	8
Tyrosine	3
Phenylalanine	3
Lysine	6
Histidine	2
Arginine	5

Approximate Total:  $\frac{89}{5}$

the amino acids cysteic, hydroxproline, norleucine, ammonia, isodesmosine, hydroxylysine, lysinonorleucine and gamma-aminobutyric acid being absent in detectable amounts.

*32*  
Claim ~~30~~<sup>32</sup>. A process for purifying intact anti-MALIGNIN comprising fractionating said intact anti-MALIGNIN by chromatographic separation to produce sub-fractions distinguishable from each other in terms of their content of intact anti-MALIGNIN protein and smaller molecular weight fractions identifiable as Fab or F<sub>c</sub> components.

*33*  
Claim ~~31~~<sup>33</sup>. The products produced by the process of claim ~~30~~<sup>32</sup>.

REMARKS

Reconsideration of this application is respectfully requested.

The claims presented for examination are claims 13 through 31.

The Examiner has objected to the use in the originally presented claims of a variety of terms for which he feels further definition therein is required. Applicant respectfully urges that the claims as presently formulated are, in fact, in compliance with 35 U.S.C. §112. However, it is appreciated that much of this subject matter, and the terminology used herein, is no doubt new to the Examiner. For this reason, applicant will endeavor herein to provide information, background and otherwise, which hopefully will enable the Examiner to more fully appreciate the novel features of the claimed invention.